Sanofi Beats Q3, Lifts 2026 Outlook as Dupixent Tops €5.7B
SNY is trading near its 52-week low of $39.07 (10% above the low).
Summary
Sanofi beat third-quarter estimates and raised its full-year 2026 guidance. Business EPS came in at €3.55, €2.04 above consensus, and revenue rose 16.2% year over year to €14.44B, €1.12B ahead of expectations. Dupixent did the heavy lifting: sales climbed 34.8% to €5.7B, clearing the €5.2B analysts expected and crossing the €5B quarterly mark for the second time. The launches portfolio added €1.4B, up 31.4%, while vaccines slipped 6.6% to €3.2B on anticipated respiratory-season phasing. Management now expects full-year sales growth in the low teens at constant exchange rates, up from 10%, and business EPS growth in the mid-teens at CER. The raise is the key item — it resets the earnings base higher rather than just confirming the quarter.
At the time of this announcement, SNY was trading at $43.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.1B. The 52-week trading range was $39.07 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.